Finally, the use of multiple genomic alteration detection methods, such as NGS, in NSCLC with acquired resistance to previous bevacizumab combined with erlotinib therapy increases in clinical practice, and resistant genomic alterations other than T790M, such as MET, HER2 or BRAF, can be detected by NGS (29). This evidence concerns the gene BRAF and non-small cell lung carcinoma.